Treatment of Cytomegalovirus Pneumonia in Pregnancy
Cytomegalovirus (CMV) pneumonia during pregnancy requires a defined treatment approach. Below is a summary of the clinical scenario, what treatment involves, and what success looks like — with the full structured protocol available via the link below.
During pregnancy, indications for treatment of CMV infection are the same as for other people with HIV. Valganciclovir is the preferred treatment for maternal CMV disease during pregnancy.
The preferred approach involves an oral antiviral agent, with therapy duration guided by established adult CMV management principles. The full regimen — including specific dosing, sequencing, and duration parameters — is detailed in the structured protocol.
Treatment targets resolution of the signs and symptoms of CMV pneumonia — fever, cough or dyspnea, and diffuse pulmonary interstitial infiltrates — over an adequate course of therapy.
References
- During pregnancy, indications for treatment of CMV infection are the same as for other people with HIV (AIII).
- Valganciclovir is the preferred treatment for maternal CMV disease during pregnancy (BIII).
- Duration of anti-CMV therapy should follow guidance for nonpregnant adults.
- ≥21 days or until signs and symptoms have resolved (CII).